Division of Basic Science, Fred Hutchinson Cancer Research Center (FHCC), Seattle, WA, United States.
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Front Immunol. 2023 May 3;14:1170462. doi: 10.3389/fimmu.2023.1170462. eCollection 2023.
MHC class I "" molecules, coupling MHC heavy chain, β-microglobulin, and a specific peptide into a single polypeptide chain, are widely used in research. To more fully understand caveats associated with this design that may affect its use for basic and translational studies, we evaluated a set of engineered single-chain trimers with combinations of stabilizing mutations across eight different classical and non-classical human class I alleles with 44 different peptides, including a novel human/murine chimeric design. While, overall, single-chain trimers accurately recapitulate native molecules, care was needed in selecting designs for studying peptides longer or shorter than 9-mers, as single-chain trimer design could affect peptide conformation. In the process, we observed that of peptide binding were often discordant with and that yields and stabilities varied widely with construct design. We also developed novel reagents to improve the crystallizability of these proteins and confirmed novel modes of peptide presentation.
MHC Ⅰ类“分子”将 MHC 重链、β-微球蛋白和特定肽连接成单一多肽链,广泛用于研究。为了更全面地了解可能影响其用于基础和转化研究的这一设计的注意事项,我们评估了一组具有 8 种不同经典和非经典人类 I 类等位基因的稳定突变组合的工程化单链三聚体,共有 44 种不同的肽,包括一种新型的人/鼠嵌合设计。虽然单链三聚体总体上准确地再现了天然分子,但在选择用于研究长于或短于 9 个氨基酸的肽的设计时需要谨慎,因为单链三聚体设计可能会影响肽的构象。在此过程中,我们观察到,与 相比,肽结合的 经常不一致,并且构建设计的变化会导致产量和稳定性广泛变化。我们还开发了新的试剂来提高这些蛋白质的结晶能力,并证实了新的肽呈递模式。